Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

A case of mixed adenoneuroendocrine carcinoma of the pancreas: Immunohistochemical analysis for histogenesis.

Murata M, Takahashi H, Yamada M, Song M, Hiratsuka M.

Medicine (Baltimore). 2017 Mar;96(9):e6225. doi: 10.1097/MD.0000000000006225.

2.

A mixed adenoneuroendocrine carcinoma of the pancreas: a case report.

Imaoka K, Fukuda S, Tazawa H, Kuga Y, Mochizuki T, Hirata Y, Fujisaki S, Takahashi M, Nishida T, Sakimoto H.

Surg Case Rep. 2016 Dec;2(1):133. Epub 2016 Nov 15.

3.

Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma.

Ando T, Hosokawa A, Yoshita H, Ueda A, Kajiura S, Mihara H, Nanjo S, Fujinami H, Nishikawa J, Ogawa K, Nakajima T, Imura J, Sugiyama T.

Gastroenterol Res Pract. 2015;2015:425876. doi: 10.1155/2015/425876. Epub 2015 Jun 23.

4.

Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas.

Ramella Munhoz R, de Mendonça Rego JF, de Celis Ferrari AR, Ignez Braghiroli M, Mendonça Bariani G, Marcelo Hoff P, Perego Costa F, Eduardo Flesch Pfiffer T, Riechelmann R.

Rare Tumors. 2013 Sep 4;5(3):e39. doi: 10.4081/rt.2013.e39. eCollection 2013.

5.

Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors.

Ferrarotto R, Testa L, Riechelmann RP, Sahade M, Siqueira LT, Costa FP, Hoff PM.

Rare Tumors. 2013 Sep 24;5(3):e35. doi: 10.4081/rt.2013.e35. eCollection 2013.

6.

A multimodal approach to the management of neuroendocrine tumour liver metastases.

Basuroy R, Srirajaskanthan R, Ramage JK.

Int J Hepatol. 2012;2012:819193. doi: 10.1155/2012/819193. Epub 2012 Feb 15.

7.

Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.

Oberstein PE, Saif MW.

Clin Med Insights Oncol. 2012;6:41-51. doi: 10.4137/CMO.S7319. Epub 2012 Jan 4.

8.

Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies.

Schmidt C, Bloomston M, Shah MH.

Oncogene. 2011 Mar 31;30(13):1497-505. doi: 10.1038/onc.2010.548. Epub 2010 Dec 6. Review.

9.

New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors.

Lawrence B, Gustafsson BI, Kidd M, Modlin I.

Gastroenterol Clin North Am. 2010 Sep;39(3):615-28. doi: 10.1016/j.gtc.2010.08.013. Review.

10.

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.

Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L.

Cancer. 2011 Jan 15;117(2):268-75. doi: 10.1002/cncr.25425. Epub 2010 Sep 7.

11.

Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases.

van Iersel LB, Hoekman EJ, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Hartgrink HH, Kuppen PJ, Nortier JW, Tollenaar RA, van de Velde CJ.

Ann Surg Oncol. 2008 Jul;15(7):1891-8. doi: 10.1245/s10434-008-9881-6. Epub 2008 May 10.

Supplemental Content

Support Center